TABLE 4.

Atabrine exacerbates plasmochin-induced methemoglobinemia, whereas quinine fails to impact plasmochin-induced methemoglobinemia

Treatment	No. of subjects	Mean % of MetHba	SD (range) of % of MetHb
Plasmochin or plasmochin-atabrineb
30 mg	29	4.4	2.4 (0.7–10.0)
60 mg	13	8.9	4.5 (1.9–20.8)
90 mg	24	12.2	7.0 (0.9–28.7)
30 mg + atabrine (dose not specified)	6	12.2	4.6 (6.0–19.3)
Plasmochin-quininec
31.5 mg	12	4.4	3.7 (2.1–15.8)
63 mg	6	12.8	4.1 (7.2–21.4)
15 mg + quinine	10	2.5	0.7 (1.3–3.6)
31.5 mg + quinine	27	4.5	2.1 (1.7–9.2)
63 mg + quinine	76	10.7	4.9 (2.9–24.0)

^aMetHb, methemoglobin.

^bAdapted from reference 151 with permission of the American Society for Clinical Investigation.

^cBased on data from Clayman et al. (59).